Panelists discuss how they incorporate both steroids and nonsteroidals from the initial visit by limiting steroid use to 1 to 2 weeks followed by long-term nonsteroidal maintenance, while noting the need for more vehicle formulations and lower age indications to better serve younger patients with limited treatment options.
Panelists discuss how extensive body surface area involvement in pediatric patients affects topical prescribing decisions, with high coverage areas often requiring systemic therapy consideration. They also discuss how location-specific factors like sensitive areas (face, groin) influence the choice toward nonsteroidal agents over topical steroids.
A new IPC-endorsed framework simplifies psoriasis severity into “topical” versus “systemic” categories to guide treatment more effectively, according to James Song, MD.
Peter Lio, MD, describes Fall Clinical as an energizing, high-level dermatology meeting focused on practical takeaways and collaboration.
Biologics, JAK inhibitors, and evolving treatment paradigms headline the Fall Clinical 2025 agenda.
Discover non-clinical career paths for PAs and NPs at the 2025 PDPA Keystone Conference, featuring insights from Shanna Miranti, MPAS, PA-C, and Lauren Miller, PA-C.
Cemiplimab is revolutionizing treatment for high-risk cutaneous squamous cell carcinoma, bridging gaps in care and improving patient outcomes.
Panelists discuss how postinflammatory hyperpigmentation (PIH) from acne requires simultaneous treatment of both the underlying acne and the resulting pigmentation using retinoids as first-line therapy, salicylic acid for exfoliation, and newer cosmeceuticals that can be tolerated even during isotretinoin therapy, emphasizing that treating pigmentation alone without addressing active acne is ineffective.
Panelists discuss how chemical peel selection must consider Fitzpatrick skin type with superficial peels safe for all patients while medium-depth peels require careful application in darker skin, and how treatment adherence is affected by multiple factors including application frequency, cost burden, insurance coverage limitations, and the need to manage patient expectations while accounting for concurrent use of social media–influenced products.
Vimal Prajapati, MD, FRCPC, DABD, highlights the durable efficacy of guselkumab, reassuring safety, and quality-of-life improvements in pediatric patients with moderate to severe plaque psoriasis.
Vishal A. Patel, MD, discusses cemiplimab's FDA approval as a groundbreaking adjuvant therapy for high-risk cutaneous squamous cell carcinoma patients.
A panelist discusses how evolving trial standards and long-term safety considerations are redefining efficacy benchmarks and the role of oral systemics in psoriasis management.
The episode underscores the clinical value of listening to patient advocates who bring firsthand understanding of disease impact.
Vimal Prajapati, MD, FRCPC, DABD, highlights guselkumab’s ability to achieve high levels of skin clearance in pediatric patients with moderate to severe plaque psoriasis.
Kachiu Lee, MD, MPH, FAAD, shares insights on aesthetic dermatology at the 2025 PDPA Keystone, emphasizing trust and communication over technology for optimal results.
Panelists discuss how the current topical standard of care has evolved from traditional topical steroids developed in the 1960s to include newer nonsteroidal options like ruxolitinib (Janus kinase [JAK] inhibitor), roflumilast (phosphodiesterase-4 [PDE4] inhibitor), and tapinarof (aryl hydrocarbon receptor agonist), with steroids now serving as bridge treatments rather than long-term maintenance therapy.
Panelists discuss how atopic dermatitis presents differently across pediatric age groups. Infants show lesions on cheeks and extensor surfaces, whereas older children develop more typical flexural patterns. They also discuss how the condition significantly impacts the quality of life for patients and caregivers through sleep disruption, school performance issues, and ongoing parental stress.
Panelists discuss how thiamidol has shown real-world success in treating stippled postinflammatory hyperpigmentation (PIH) from acne picking when applied 4 times daily alongside retinoids and chemical peels, with the key being proper product layering and selecting adherent patients who can manage multiple daily applications.
Panelists discuss how nonhydroquinone agents, such as thiamidol, demonstrate excellent tolerability profiles in data from head-to-head studies and how combination therapies including chemical peels, picosecond lasers, microneedling with transdermal delivery, and oral tranexamic acid can be used as adjunctive treatments for stubborn melasma cases that plateau with topical therapy alone.
If passed, the Safe Step Act could reduce treatment delays by prohibiting step therapy for FDA-labeled, guideline-supported agents.
Panelists discuss how OX40-pathway therapies may serve as first-line treatments after topicals due to their promising efficacy and safety profiles, though questions remain about optimal patient selection, long-term safety, and predictive biomarkers.
Panelists discuss how multiple OX40 pathway–targeted drugs are in development, including rocatinlimab (anti-OX40, cell depleting) and amlitelimab (anti-OX40L, nondepleting), both showing promising phase 2/3 results with potential for sustained responses.
Amy Lewis, MD, integrates Glo2Facial into her practice to enhance patient relationships and promote early skin health through innovative aesthetic treatments.
Panelists discuss how dermatologists play a vital role in helping patients navigate the overwhelming variety of skin care products by emphasizing simple, gentle, and fragrance-free routines focused on cleansing, moisturizing, and protection—highlighting that consistency and patience are key to restoring skin barrier health, especially in sensitive skin. They also stress that effective skin care does not require expensive products, and tailoring regimens with evidence-supported ingredients like polymeric surfactants and lipid-based moisturizers improves adherence and outcomes.
Panelists discuss a recent study showing that once-daily application of a moisturizer over 4 weeks significantly improved skin hydration, texture, and radiance, with benefits persisting even after discontinuation—highlighting the lasting impact of well-formulated products on skin barrier health. They also emphasize the importance of tailoring moisturizer types, such as lighter gels for acne-prone skin and richer creams for dry or compromised skin, to address specific patient needs and sensitivities for optimal outcomes.
Panelists discuss recent studies on advanced moisturizers that not only provide immediate hydration but also stimulate the skin’s natural production of key proteins and lipids, such as aquaporin-3 and filaggrin, leading to sustained improvements in barrier function and skin health—benefits that are particularly important for individuals with sensitive or compromised skin and support the need for consistent, targeted moisturizing in clinical care.
Discover how the Glo2Facial revolutionizes aesthetic dermatology with innovative skin oxygenation and customizable treatments for radiant, youthful skin.
A late-breaking EADV presentation revealed that ritlecitinib significantly improved outcomes in patients with multiple forms of scarring alopecia.
The biologic’s less frequent injections could ease logistical and emotional strain for patients with atopic dermatitis and their families.
Lipella Pharmaceuticals' LP-10 shows promise as a targeted treatment for OLP, offering safety and efficacy in recent trials, according to Michael Chancellor, MD.
